

ABSTRACT

Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: control group (CG) and intervention group (IG). The CG received no intervention, while the IG received a 6-week intervention program. The outcome measures were measured at baseline, post-intervention, and follow-up.